- Home
- IONS vs IDA Comparison
IONS vs IDA Comparison
Compare IONS & IDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IONS
- IDA
- Stock Information
- Founded
- IONS 1989
- IDA 1915
- Country
- IONS United States
- IDA United States
- Employees
- IONS N/A
- IDA N/A
- Industry
- IONS Biotechnology: Pharmaceutical Preparations
- IDA Electric Utilities: Central
- Sector
- IONS Health Care
- IDA Utilities
- Exchange
- IONS Nasdaq
- IDA Nasdaq
- Market Cap
- IONS 6.8B
- IDA 6.3B
- IPO Year
- IONS 1991
- IDA N/A
- Fundamental
- Price
- IONS $42.25
- IDA $123.24
- Analyst Decision
- IONS Buy
- IDA Buy
- Analyst Count
- IONS 15
- IDA 7
- Target Price
- IONS $57.13
- IDA $122.86
- AVG Volume (30 Days)
- IONS 1.8M
- IDA 481.3K
- Earning Date
- IONS 07-30-2025
- IDA 07-31-2025
- Dividend Yield
- IONS N/A
- IDA 2.79%
- EPS Growth
- IONS N/A
- IDA 12.96
- EPS
- IONS N/A
- IDA 5.63
- Revenue
- IONS $717,253,000.00
- IDA $1,810,154,000.00
- Revenue This Year
- IONS $9.08
- IDA $5.33
- Revenue Next Year
- IONS $14.72
- IDA $10.24
- P/E Ratio
- IONS N/A
- IDA $21.91
- Revenue Growth
- IONS N/A
- IDA 1.37
- 52 Week Low
- IONS $23.95
- IDA $96.87
- 52 Week High
- IONS $52.34
- IDA $125.42
- Technical
- Relative Strength Index (RSI)
- IONS 60.76
- IDA 72.84
- Support Level
- IONS $41.25
- IDA $121.76
- Resistance Level
- IONS $42.81
- IDA $125.42
- Average True Range (ATR)
- IONS 1.18
- IDA 1.88
- MACD
- IONS -0.27
- IDA 0.59
- Stochastic Oscillator
- IONS 42.36
- IDA 80.93
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.
About IDA IDACORP Inc.
Idacorp Inc is a holding company that, through its subsidiaries, acts as an electric utility engaged in the generation, transmission, distribution, sale, and purchase of electric energy and capacity. The companys only reportable segment is utility operations. The utility operations segment's primary source of revenue is the regulated operations of Idaho Power. The company serves commercial and industrial customers, which involved in food processing, electronics and general manufacturing, agriculture, health care, government, and education.